Squarepoint
VIVO

Squarepoint’s Meridian Bioscience Inc VIVO Stock Holding History

Squarepoint’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-39,232
Closed -$1.3M – 4008
2022
Q4 		$1.3M Buy
39,232
+20,213
+106% +$651K 0.01% 1637
2022
Q3 		$600K Buy
+19,019
New +$616K ﹤0.01% 2114
2022
Q1 		– Sell
-36,686
Closed -$748K – 3788
2021
Q4 		$748K Buy
+36,686
New +$703K ﹤0.01% 1880
2020
Q3 		– Sell
-36,745
Closed -$856K – 2961
2020
Q2 		$856K Sell
36,745
-8,757
-19% -$127K 0.01% 1032
2020
Q1 		$382K Sell
45,502
-46,293
-50% -$390K 0.01% 1181
2019
Q4 		$897K Buy
91,795
+32,999
+56% +$310K 0.01% 1400
2019
Q3 		$558K Sell
58,796
-15
-0% -$158 0.01% 1561
2019
Q2 		$699K Buy
58,811
+31,764
+117% +$383K 0.01% 1467
2019
Q1 		$476K Sell
27,047
-25,468
-48% -$424K 0.01% 1509
2018
Q4 		$912K Buy
+52,515
New +$896K 0.01% 963
2018
Q1 		– Sell
-39,524
Closed -$553K – 2290
2017
Q4 		$553K Buy
+39,524
New +$579K 0.01% 1146
2017
Q3 		– Sell
-18,574
Closed -$293K – 1964
2017
Q2 		$293K Buy
+18,574
New +$268K 0.01% 1145

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Squarepoint's VIVO Position: Q1 2023 in Review

Squarepoint sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 39,232 shares — an estimated $1.3M sold.

Squarepoint first reported a position in VIVO in Q2 2017 and held it in 12 quarters. The position peaked at $1.3M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Squarepoint reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Squarepoint sold 39,232 Meridian Bioscience Inc shares in Q1 2023, an estimated $1.3M.
  • Squarepoint first reported a position in Meridian Bioscience Inc in Q2 2017 and held it in 12 quarters.
  • Squarepoint's Meridian Bioscience Inc position peaked at $1.3M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Squarepoint's 13F filing for Q1 2023, filed 15 May 2023.